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On the structure-activity relationships of 1,3,7-alkylxanthines on PDE 4 isoenzyme inhibitors, we reported that the 3-substituents increased both tracheal-relaxant action and positive-chronotropic action, and 1-or 7-substituents were important for bronchoselectivity. 1) Also, denbufylline (DBF) and XT-44 were effective against osteoporosis in animal models.
2) Further, we discovered that the heterocycle[i]condensed-purines (3a-f), especially 3c (R 3 ϭnPr, nϭ2) had potent PDE 4 inhibitory activity and lacked some of the adverse reactions of xanthine derivatives. 3) From Vega's report that 3-( p-chlorophenyl)-1-propylxanthine (1) showed potent bronchodilator activity, 4) we assumed that PDE 4-inhibitory activity was closely related to the increase of the partition coefficients owning to the replacement of alkyl group to aryl group at 3-position.
The above presumption prompted us to examine PDE 4-inhibitory activities of the corresponding phenyl substituted derivatives (2, 4a-f) for comparison with those of DBF and 3a-f. In this paper, we describe the synthesis and inhibitory activity of phenyl substituted derivatives.
Synthesis 3-Phenyl-7-propylxanthine (6) was prepared from 3-phenylxanthine (5) 4) by treatment with n-propyl bromide in the presence of potassium carbonate. 7-Acetonyl-1-n-butyl-3-phenylxanthine (2) was prepared by the following route: 7-benzyl-3-phenylxanthine (7), obtained from 5 by benzylation at 7-position, was alkylated with n-butyl bromide at 1-position and then treated with 20% palladium hydroxide on carbon to give 1-butyl-3-phenylxanthine (9), which afforded 2 by alkylation with bromoacetone in the presence of potassium carbonate (Chart 2).
4-Phenyltetrahydroimidazo[i]purine (4a, b) and 4-phenyltetrahydropyrimido[i]purine (4d, e) were prepared by the following route: treatment of 3-phenylxanthine (5; RϭH and 6; RϭnPr) with Lawesson's reagent or phosphorus pentasulfide, respectively, gave 3-phenyl-6-thioxoxanthine (10a, b), which were treated with 2-aminoethanol or 3-aminopropanol to give the corresponding 6-hydroxyalkyl compounds (11a, b, d, e). 11a, b, d, and e were treated with methanesulfonyl chloride in the presence of triethylamine to afford the corresponding 4-phenyl[i]condensed-purines (4a, b, d, e) (Chart 3).
Attempts to synthesize 4c and f (RϭnPr) from 4b and e (RϭH) by treatment with n-propyl bromide in the presence of potassium carbonate were unsuccessful. These products were unexpectedly 4a and 4d, although the synthesis of 3c and 3f having 3-n-propyl group had been achieved by similar treatment of 3b and 3e. 3) These results indicate that the steric hindrance by the replacement of 3-n-propyl group to 3-phenyl group might have occurred.
Biological Results and Discussion
The inhibitory activities of 3-phenylxanthines (2, 5, 6, 9) and 4-phenyl[i]condensed-purines (4a, b, d, e) against PDE 1 and 4 isoenzymes from a guinea-pig brain and PDE 3 from a guinea-pig heart were measured according to the published methods.
3) The results are shown in Table 1 together with PDE inhibitory activities of known PDE 4 inhibitors DBF, XT-44 and 3c.
These compounds showed no or very weak inhibitory activity against PDE 1 and 3 isoenzymes. Compound 5, having no alkyl group at other N-positions, was inactive, but the alkyl group at 1-or 7-position (6, 9) induced PDE 4 inhibitory activity. On the other hand, although DBF is a potent and selective PDE 4 inhibitor, its 3-phenyl derivative (2) showed much less activity than the parent compound DBF and 9 without 7-acetonyl group.
Heterocycle-condensed purines, 4b and 4e, which have no alkyl group at the purine skeleton, were inactive, but compounds 4a and 4d, having n-propyl group, showed PDE 4 inhibitory activity. Especially, compound 4d inhibited stronger than 4a, and with equal or more potency than the reference PDE 4 inhibitors.
Previously, we found that prolongation of the alkyl chain length at the 3-position of the xanthine skeleton increased bronchodilator activity, which is closely related with their PDE 4 inhibitory activity. In addition, we discovered that adverse effects, such as tachycardia, related with their PDE 3 inhibitory activity, and excitation of the central nervous system may be related with their PDE 1 inhibitory activity, and substitution of long alkyl groups at 1-position induced selective PDE 4 inhibitory activity. Consequently, we developed XT-44.
1) Moreover, we indicated that 3-n-propyl[i]condensed-purines showed selective PDE 4 inhibitory activity and the smaller condensed ring showed stronger inhibitory activity.
3) On the other hand, regarding 3-phenylpurines in this study, the larger heterocycle ring showed stronger inhibitory activity against PDE 4 isoenzyme.
In conclusion, this study indicated that both xanthines and condensed-purines substituted with the phenyl group showed potent and selective PDE 4 inhibitory activity. Table 2 and 3, respectively. 7-Propyl-3-phenylxanthine (6) To a mixture of 3-phenylxanthine (5, 500 mg, 2.19 mmol) and anhydrous K 2 CO 3 (360 mg, 2.63 mmol) in dimethylformamide (DMF, 10 ml) was added n-propyl bromide (900 mg, 5.26 mmol) at 0°C; the reaction mixture was stirred overnight at room temperature, then concentrated in vacuo. The residue was chromatogaraphed on silica gel using CHCl 3 -MeOH (20 : 1) as an eluent to give 6 (404.5 mg, 68%). mp 224-225°C (AcOEt-MeOH 1-Butyl-3-phenylxanthine (9) The mixture of 8 (620 mg, 0.166 mmol) and 20% palladium hydroxide on carbon (600 mg) in MeOH (20 ml) was shaken under hydrogen (3 atm) for 3 h. The catalyst was removed and the filtrate concentrated in vacuo, and the residue crystallized to yield 9 (450 mg, 95% 3-Phenyl-6-thioxoxanthine (10b) The mixture of 6 (2 g, 8.77 mmol) and phosphorus pentasulfide (2.42 g, 10.9 mmol) in pyridine (30 ml) was refluxed for 3 h. The reaction mixture was concentrated in vacuo, and the residue crystallized to yield 10b (1.86 g, 87%). mp Ͼ290°C (H 2 O). 6-Hydroxyalkylamino-3-phenylxanthines (11a, b, d, e) General Procedure: The mixture of 10 (1 mmol) and 2-aminoethanol or 3-aminopropanol (3 ml) in pyridine (10 ml) was refluxed for 4 h, and concentrated in vacuo. The residue was purified by silica gel column chromatography using CHCl 3 -MeOH (6 : 1) as an eluent to give 11a, b, d, and e. -purine (4a, b, d, e) General Procedure: To a mixture of 11 (0.2 mmol) and triethylamine (0.24 mmol) in CH 2 Cl 2 (5 ml) was added methanesulfonyl chloride (0.24 ml) at 0°C. The reaction mixture was stirred for 3 h at room temperature and then concentrated in vacuo. The residue was chromatographed on silica gel using CHCl 3 -MeOH (10 : 1) as an eluent to give 4a, b, d, and e.
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